Navigation Links
Nutrastar Announces Full Year 2012 Results, Issues 2013 Revenue Guidance
Date:3/29/2013

cial position, Ms. Han stated, "As vouched and verified by our independent auditor, we closed the year with a cash balance of approximately $75.5 million, equivalent to roughly $4.55 per diluted share. These funds are being managed wisely and conservatively, and are set aside for the Company's future organic and inorganic growth initiatives such as brand and product development, as well as marketing & advertising designed to promote our consumer product portfolio in cities deemed most opportunistic."

Ms. Han continued, "Looking at 2013, current demographical and market conditions in China seemingly continue to remain advantageous to our businesses and our premium consumer product offerings, particularly as the country becomes more affluent; its citizens become more health conscious; and rising healthcare costs continue to result in increasing demand for alternative medicines and preventative measures such as our core product Cordyceps. We expect this year to be one of substantial expansion in both our top and bottom line as well as within our product offerings and overall market presence. Equipped with heightened capacity, we also expect to see improvements related to our costs and operations, and anticipate that with the proper, intelligent allocation of funds, we will continue building greater market awareness for our premium functional health beverages and other products in China with the larger goal to expand distribution into the international arena. We look forward to the remainder of the year ahead and encourage any interested party to reach out to us directly for more information on Nutrastar and our innovative, premium consumer product portfolio."

Outlook for the Year Ending December 31, 2013

Based on management's current expectations, the Company projects that 2013 revenue will be in the range of $44 million to $46 million, representing an approximate 19% to 25% top line increase year over year.

Request for Call w
'/>"/>

SOURCE Nutrastar International Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
2. International Isotopes Inc. Announces 2012 Year End Financial Results
3. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
4. ShangPharma Corporation Announces Completion of Merger
5. ReSearch Pharmaceutical Services Announces Joint Venture with Asklep in Japan
6. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
7. CleanPath Resources Corp Announces Worldwide Exclusive Stem Cell Enhancement Agreement with a Division of Hemp, Inc.
8. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
9. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
10. TriReme Announces Signing of a Master Distribution Agreement in China
11. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Clinical Development for the Treatment of ... Opioid Bowel Dysfunction, ... presented positive results this week from Phase,1 and preclinical studies of ... in Las Vegas, Nevada. NKTR-118 is,Nektar,s proprietary oral therapy being studied ...
... physician leading clinical trials, FREEPORT, N.Y., ... in treating facial bruising from injectable cosmetic,treatments ... known for,treating under-eye circles. Pinoxide is ... (BMTd),created by AGI Dermatics and formulated in ...
Cached Medicine Technology:Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5Promising Results in Treating Facial Bruising From Injectables 2
(Date:6/1/2015)... 2015 On May 14, 2015, the ... hosted the Cherry Creek Chamber of Commerce for the ... care centers typically do not offer primary care services ... Cherry Creek Urgent Care staff to schedule family care ... 5:30 to 7:30 p.m. the center hosted presidents, CEOs, ...
(Date:6/1/2015)... Portland, Ore. (PRWEB) June 01, 2015 ... Plans (AHIP) announced today a new, interactive Affordable ... support large employers. The course, called “Affordable Care ... care professionals with the strategic and consultative insights ... employers as they navigate the impacts of the ...
(Date:6/1/2015)... June 01, 2015 Note: Dr. Julian ... in breast cancer prevention. , A phase III trial ... postmenopausal women with ductal carcinoma in situ (DCIS) now ... prevention. , The study (NSABP B-35/NRG Oncology) looked at ... the standard five-year treatment with tamoxifen to those who ...
(Date:6/1/2015)... June 01, 2015 More than 22 million ... months when school is out and they lose access to ... and America’s dairy farmers and milk companies are on a ... with The Great American Milk Drive. , In many ... in the school cafeteria for the bulk of their daily ...
(Date:6/1/2015)... 2015 June 1, 2015 – Atlanta, ... in the areas of hospital medicine, emergency medicine, and ... has expanded upon its partnership with AgileMD to provide ... Practice, in a mobile application format available on ... “We are very excited about the June 1 launch ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... , ... Data Advantage, LLC recently named two QHR ... list. Fort Madison Community Hospital (Fort Madison, Iowa), a QHR management ... management client since 1979, were lauded by the company, which specializes ...
... Dec. 20 (HealthDay News) -- Think twice before you put that ... You may get it and find out you don,t really need ... a new study suggests. , That,s because "sometimes the reality of ... cappuccino machine is a hassle to clean, the fancy navigation system ...
... ... Province of Quebec following an inquiry that suggested that there might have been testing ... ... served as the reference laboratory for a highly anticipated retesting of nearly 3,000 breast ...
... , WASHINGTON, Dec. 20 ... Bureau: , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , SUNDAY, DECEMBER ... Sunday, December 20th. The first successful organ transplant in the U.S. ... Joseph Murray. He transplanted a kidney from one identical twin ...
... , , Federal government must not ... not go forward unless and until problems remedied , ... affordability top issues , WASHINGTON, Dec. 19 The ... current form, Cardinal Daniel DiNardo of Galveston-Houston, Bishop William Murphy ...
... electronic health records, concerns about potential privacy breaches remain an ... 2010 issue of the Journal of the American Informatics ... one of 30 specialty titles published by the BMJ ... published study is based on views of more than 1,000 ...
Cached Medicine News:Health News:QHR Hospital Clients Fort Madison Community Hospital, Monroe County Hospital Named to “Best in Value” Top 100 List 2Health News:Be Careful What You Wish For This Holiday Season 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 3Health News:U.S. Census Bureau Daily Feature for Dec. 20 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 3Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 4Health News:Journal of the American Medical Informatics Association 2
Ruschelit® PVC. Magill tip-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Gradua...
Laser resistant tubes for use with CO2 and KTP Lasers., ,Designed for airway management during laser surgery of the larynx or other areas in close proximity to the trachea....
Medicine Products: